Cancer Therapies

Investigational New Drug Application Filed for Dolastatin Analog

Published in Cancer Weekly, January 23rd, 2001

Ilex Products Inc., announced January 3, 2001, that it had submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to test the investigational drug ILX-651, one of a new class of orally active compounds being evaluated for their potential anticancer properties.

ILX-651 is a synthetic pentapeptide analog of dolastatin, with a mechanism of action that is analogous to taxanes (e.g., TAXOL^R and Taxotere^R). A tubulin interactive, anti-mitotic compound, ILX-651 appears to be active in taxane-resistant tumors in preclinical animal models in human breast carcinoma. It also appears to be active for a variety...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry